uniQure N.V. | Mutual Funds
Mutual Funds that own uniQure N.V.
Federated Kaufmann Fund
852,471
2.29%
852,471
0.53%
06/29/2018
Fidelity Growth Company Fund
840,254
2.25%
-4,559
0.07%
07/31/2018
Fidelity Special Situations Fund
609,232
1.64%
0
1.4%
07/31/2018
Delaware Healthcare Fund
590,000
1.59%
58,551
3.83%
03/31/2018
Fidelity Select Health Care Portfolio
527,338
1.42%
3,000
0.3%
07/31/2018
Fidelity OTC Portfolio
523,800
1.41%
8,800
0.1%
07/31/2018
Eventide Healthcare & Life Sciences Fund
475,350
1.28%
140,350
2.91%
06/29/2018
iShares Nasdaq Biotechnology ETF
418,520
1.12%
-5,481
0.18%
09/06/2018
Catalyst Eventide Gilead Fund
278,700
0.75%
278,700
0.64%
06/29/2018
255,618
0.69%
0
0.71%
07/31/2018
| Address |
Paasheuvelweg 25a
Amsterdam Noord-Holland 1105 BP
Netherlands
|
|
Employees
|
- |
| Website |
http://www.uniqure.com |
| Updated |
07/08/2019 |
| uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands. |
